0.9000
13-فبراير-25 16:45:00
15 متأخرة بدقائق
الأسهم
+0.0101
+1.13%
نطاق اليوم
0.8700 - 0.9150
ISIN
N/A
المصدر
NASDAQ
IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian Cancer
18 أكتوبر 2023 08:30:00 بحسب Nasdaq GlobeNewswire
IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board
06 أكتوبر 2023 08:30:00 بحسب Nasdaq GlobeNewswire